Drugs / Allisartan Isoproxil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04111419 | Jul 2020 → Sep 2026 overdue | atrial fibrillation, hypertensive disorder | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 3 | NCT06500689 Comparator | Dec 2021 → Nov 2023 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06465264 Comparator | Apr 2021 → Aug 2022 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT07174830 Comparator | Sep → Dec 2025 overdue | — | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 4 | NCT04978649 Comparator | Sep 2021 → Jul 2026 | hypertensive disorder, type 2 diabetes mellitus | Guangdong Provincial People's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03264352 Comparator | Feb 2018 → Sep 2028 expected | hypertensive disorder, type 2 diabetes mellitus | XueQing Yu | Recruiting | No outcome recorded |
| Phase 4 | NCT02893358 Comparator | Feb 2017 → Oct 2021 | hypertensive disorder | Yan Li | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allisartan Isoproxil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03264352 ↗ |
| Action | Inhibit | “an angiotensin type-1 receptor blocker Allisartan (240 mg/day)” NCT03264352 ↗ |